<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="retraction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1337635</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Editorial Office</collab>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>Approved by: Giuseppe Giaccone, Vice President Global Development, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Frontiers Editorial Office, <email xlink:href="mailto:research.integrity@frontiersin.org">research.integrity@frontiersin.org</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1337635</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>11</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Frontiers Editorial Office</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Frontiers Editorial Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" xlink:href="10.3389/fonc.2020.588533" ext-link-type="doi">A Retraction of the Original Research Article <article-title>Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin</article-title> by Li B, Zhao X, Zhang L and Cheng W (2021) <italic>Front. Oncol.</italic> 10:588533. doi: <object-id>10.3389/fonc.2020.588533</object-id>
</related-article>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="1"/>
<word-count count="110"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The journal retracts the February 2021 article cited above.</p>
<p>Following publication, the authors contacted the Editorial Office to request the retraction of the cited article, stating concerns regarding the use of an incorrect dataset in the published article. It was confirmed by the authors when they tried to repeat their experiments unsuccessfully. The findings and conclusions reported in the article are no longer supported by the data. An investigation was conducted in in accordance with Frontiers&#x2019; policies that confirmed this; therefore, the article is retracted.</p>
<p>This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.</p>
</body>
</article>
